{"pmid":32483909,"title":"Renal Infarct in a COVID-19 Positive Kidney-Pancreas Transplant Recipient.","text":["Renal Infarct in a COVID-19 Positive Kidney-Pancreas Transplant Recipient.","The novel coronavirus disease 2019 (COVID-19) is associated with increased risk of thromboembolic events, but the extent and duration of this hypercoagulable state remains unknown. We describe the first case report of renal allograft infarction in a 46-year-old kidney-pancreas transplant recipient with no prior history of thromboembolism, who presented 26 days after diagnosis of COVID-19. At the time of renal infarct, he was COVID-19 symptom free and repeat test for SARS-CoV-2 was negative. This case report suggests that a hypercoagulable state may persist even after resolution of COVID-19. Further studies are required to determine thromboprophylaxis indications and duration in solid organ transplant recipients with COVID-19.","Am J Transplant","Xu, Jieqing Jessica","Samaha, Daniel","Mondhe, Suhas","Massicotte-Azarniouch, David","Knoll, Gregory","Ruzicka, Marcel","32483909"],"abstract":["The novel coronavirus disease 2019 (COVID-19) is associated with increased risk of thromboembolic events, but the extent and duration of this hypercoagulable state remains unknown. We describe the first case report of renal allograft infarction in a 46-year-old kidney-pancreas transplant recipient with no prior history of thromboembolism, who presented 26 days after diagnosis of COVID-19. At the time of renal infarct, he was COVID-19 symptom free and repeat test for SARS-CoV-2 was negative. This case report suggests that a hypercoagulable state may persist even after resolution of COVID-19. Further studies are required to determine thromboprophylaxis indications and duration in solid organ transplant recipients with COVID-19."],"journal":"Am J Transplant","authors":["Xu, Jieqing Jessica","Samaha, Daniel","Mondhe, Suhas","Massicotte-Azarniouch, David","Knoll, Gregory","Ruzicka, Marcel"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32483909","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16089","locations":["thromboprophylaxis"],"topics":["Case Report"],"weight":1,"_version_":1668704334384201728,"score":9.490897,"similar":[{"pmid":32337790,"title":"Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.","text":["Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.","The current Coronavirus Disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme over-exposure to the mammalian target of rapamycin inhibitor everolimus, following co-administration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case-report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.","Am J Transplant","Meziyerh, Soufian","Zwart, Tom C","van Etten, Ronald W","Janson, Jeroen A","van Gelder, Teun","Alwayn, Ian P J","de Fijter, Johan W","Reinders, Marlies E J","Moes, Dirk Jan A R","de Vries, Aiko P J","32337790"],"abstract":["The current Coronavirus Disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme over-exposure to the mammalian target of rapamycin inhibitor everolimus, following co-administration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case-report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients."],"journal":"Am J Transplant","authors":["Meziyerh, Soufian","Zwart, Tom C","van Etten, Ronald W","Janson, Jeroen A","van Gelder, Teun","Alwayn, Ian P J","de Fijter, Johan W","Reinders, Marlies E J","Moes, Dirk Jan A R","de Vries, Aiko P J"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337790","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15943","e_drugs":["Everolimus","Chloroquine","lopinavir-ritonavir drug combination"],"topics":["Case Report"],"weight":1,"_version_":1666138494230069248,"score":228.01244},{"pmid":32277555,"title":"Novel Coronavirus (SARS-CoV-2) Infection in A Renal Transplant Recipient: Case Report.","text":["Novel Coronavirus (SARS-CoV-2) Infection in A Renal Transplant Recipient: Case Report.","An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in Wuhan, China, with cases now confirmed in multiple countries. The clinical course of patients remains to be fully characterized, clinical presentation ranges from asymptomatic infection to acute respiratory distress syndrome and acute renal failureno pharmacological therapies of proven efficacy yet exist. We report a case of SARS-CoV-2 infection in a renal transplant recipient with excellent outcome. This case states the importance of close monitoring of the concentration of ciclosporin in patients treated with lopinavir/ritonavir, routine treatment of corticosteroid can be continued. This is a rare report of SARS-CoV-2 infection in a renal transplant recipient. Further data are needed to achieve better understanding of the impact of immunosuppressive therapy on the clinical presentation, severity and outcome of SARS-CoV-2 infections in solid organ transplant recipients.","Am J Transplant","Ning, Ling","Liu, Lei","Li, Wenyuan","Liu, Hongtao","Wang, Jizhou","Yao, Ziqin","Zhang, Shengyu","Zhao, Desheng","Nashan, Bjorn","Shen, Aizong","Liu, Lianxin","Li, Lei","32277555"],"abstract":["An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in Wuhan, China, with cases now confirmed in multiple countries. The clinical course of patients remains to be fully characterized, clinical presentation ranges from asymptomatic infection to acute respiratory distress syndrome and acute renal failureno pharmacological therapies of proven efficacy yet exist. We report a case of SARS-CoV-2 infection in a renal transplant recipient with excellent outcome. This case states the importance of close monitoring of the concentration of ciclosporin in patients treated with lopinavir/ritonavir, routine treatment of corticosteroid can be continued. This is a rare report of SARS-CoV-2 infection in a renal transplant recipient. Further data are needed to achieve better understanding of the impact of immunosuppressive therapy on the clinical presentation, severity and outcome of SARS-CoV-2 infections in solid organ transplant recipients."],"journal":"Am J Transplant","authors":["Ning, Ling","Liu, Lei","Li, Wenyuan","Liu, Hongtao","Wang, Jizhou","Yao, Ziqin","Zhang, Shengyu","Zhao, Desheng","Nashan, Bjorn","Shen, Aizong","Liu, Lianxin","Li, Lei"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277555","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1111/ajt.15897","locations":["Wuhan","China","ciclosporin"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination","Cyclosporine"],"topics":["Case Report"],"weight":1,"_version_":1666138491613872130,"score":226.92784},{"pmid":32315122,"title":"COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient.","text":["COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient.","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly infecting people worldwide, resulting in the infectious disease coronavirus disease 19 (COVID-19) that has been declared a pandemic. Much remains unknown about COVID-19, including its effects on solid organ transplant (SOT) recipients. Given their immunosuppressed state, SOT recipients are presumed to be at high risk of complications with viral infections such as SARS-CoV-2. Limited case reports in single SOT recipients, however, have not suggested a particularly severe course in this population. In this report, we present a dual-organ (heart/kidney) transplant recipient who was found to have COVID-19 and, despite the presence of a number of risk factors for poor outcomes, had a relatively mild clinical course.","Am J Transplant","Hsu, Jeffrey J","Gaynor, Pryce","Kamath, Megan","Fan, Ashley","Al-Saffar, Farah","Cruz, Daniel","Nsair, Ali","32315122"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly infecting people worldwide, resulting in the infectious disease coronavirus disease 19 (COVID-19) that has been declared a pandemic. Much remains unknown about COVID-19, including its effects on solid organ transplant (SOT) recipients. Given their immunosuppressed state, SOT recipients are presumed to be at high risk of complications with viral infections such as SARS-CoV-2. Limited case reports in single SOT recipients, however, have not suggested a particularly severe course in this population. In this report, we present a dual-organ (heart/kidney) transplant recipient who was found to have COVID-19 and, despite the presence of a number of risk factors for poor outcomes, had a relatively mild clinical course."],"journal":"Am J Transplant","authors":["Hsu, Jeffrey J","Gaynor, Pryce","Kamath, Megan","Fan, Ashley","Al-Saffar, Farah","Cruz, Daniel","Nsair, Ali"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315122","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15936","topics":["Case Report"],"weight":1,"_version_":1666138493435248640,"score":217.77975},{"pmid":32324331,"title":"Covid-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine.","text":["Covid-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine.","Coronavirus disease 2019 (Covid-19) pneumonia has been poorly reported in solid-organ transplanted patients; prognosis is uncertain and best management unclear. We describe the case of a 61-year-old kidney transplant recipient with several co-morbidities who was hospitalized and later received a diagnosis of Covid-19 pneumonia; the infection was successfully managed with the use of hydroxychloroquine and a single administration of Tocilizumab, after immunosuppression reduction; the patient did not require mechanical ventilation. During the rapid spread of SARS-CoV-2 pandemic, transplant clinicians should be readily informed about new cases of Covid-19 pneumonia in solid-organ transplant recipients, with focus on therapeutic strategies employed and their outcome.","Am J Transplant","Fontana, Francesco","Alfano, Gaetano","Mori, Giacomo","Amurri, Alessio","Lorenzo, Tei","Ballestri, Marco","Leonelli, Marco","Facchini, Francesca","Damiano, Francesca","Magistroni, Riccardo","Cappelli, Gianni","32324331"],"abstract":["Coronavirus disease 2019 (Covid-19) pneumonia has been poorly reported in solid-organ transplanted patients; prognosis is uncertain and best management unclear. We describe the case of a 61-year-old kidney transplant recipient with several co-morbidities who was hospitalized and later received a diagnosis of Covid-19 pneumonia; the infection was successfully managed with the use of hydroxychloroquine and a single administration of Tocilizumab, after immunosuppression reduction; the patient did not require mechanical ventilation. During the rapid spread of SARS-CoV-2 pandemic, transplant clinicians should be readily informed about new cases of Covid-19 pneumonia in solid-organ transplant recipients, with focus on therapeutic strategies employed and their outcome."],"journal":"Am J Transplant","authors":["Fontana, Francesco","Alfano, Gaetano","Mori, Giacomo","Amurri, Alessio","Lorenzo, Tei","Ballestri, Marco","Leonelli, Marco","Facchini, Francesca","Damiano, Francesca","Magistroni, Riccardo","Cappelli, Gianni"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324331","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15935","locations":["Hydroxychloroquine"],"e_drugs":["Hydroxychloroquine","tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138493781278724,"score":208.87204},{"pmid":32181990,"title":"Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression.","text":["Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression.","The current outbreak of Coronavirus Disease 2019 (COVID-19) has raised great concern worldwide, but its impact on transplant recipients is unknown. We report here the clinical features and therapeutic course of the first reported renal transplant recipient with confirmed COVID-19 pneumonia. This is a 52-year-old man who received kidney transplantation 12 years ago. His overall clinical characteristics (symptoms, laboratory examinations, and chest CT) were similar to those of non-transplanted COVID-19 patients. Following a treatment regimen consisting of reduced immunosuppressant use and low dose methylprednisolone-based therapy, the COVID-19 pneumonia in this long-term immunosuppressive patient was successfully recovered. This effectively treated case has reference value for the future treatment of other transplant patients with COVID-19 pneumonia.","Am J Transplant","Zhu, Lan","Xu, Xizhen","Ma, Ke","Yang, Junling","Guan, Hanxiong","Chen, Song","Chen, Zhishui","Chen, Gang","32181990"],"abstract":["The current outbreak of Coronavirus Disease 2019 (COVID-19) has raised great concern worldwide, but its impact on transplant recipients is unknown. We report here the clinical features and therapeutic course of the first reported renal transplant recipient with confirmed COVID-19 pneumonia. This is a 52-year-old man who received kidney transplantation 12 years ago. His overall clinical characteristics (symptoms, laboratory examinations, and chest CT) were similar to those of non-transplanted COVID-19 patients. Following a treatment regimen consisting of reduced immunosuppressant use and low dose methylprednisolone-based therapy, the COVID-19 pneumonia in this long-term immunosuppressive patient was successfully recovered. This effectively treated case has reference value for the future treatment of other transplant patients with COVID-19 pneumonia."],"journal":"Am J Transplant","authors":["Zhu, Lan","Xu, Xizhen","Ma, Ke","Yang, Junling","Guan, Hanxiong","Chen, Song","Chen, Zhishui","Chen, Gang"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32181990","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1111/ajt.15869","keywords":["covid-19","coronavirus","immunosuppression","pneumonia","renal transplantation"],"e_drugs":["Methylprednisolone"],"topics":["Case Report"],"weight":1,"_version_":1666138492545007617,"score":206.3217}]}